A description of Valneva’s 2020 remuneration policy is included in Section 2.6.1 of the Company’s 2019 Universal Registration Document, as filed on March 30, 2020 with the AMF under No. D.20-0217.
The 2020 Remuneration Policy was adopted by the Combined Shareholders’ Meeting of June 17, 2020, by a majority of 91.15%.
The Company holds 124,322 own ordinary shares with a par value of €0.15 each, and 124,322 preferred shares with a par value of €0.01 each. The shares are recorded as treasury stock in the financial statements and the number and movements during the fiscal year are disclosed in the notes to the financial statements.
In addition, the French Autorité des Marchés Financiers (AMF), the Austrian Stock Markets Act and the Austrian Stock Corporation Act require certain disclosures in connection with transactions in own shares, which will be made available here.
Any purchase or sale of Valneva shares (FR0004056851) by members of the Management Board or Supervisory Board will be disclosed to the French Autorité des Marchés Financiers (AMF). The AMF will publish the transactions.
Disclosure on such directors’ dealings is made available on the website of the French Autorité des Marchés Financiers (AMF).
On September 27, 2018 Valneva announced that it has raised €50 million of gross proceeds in a private placement of its ordinary shares.
Rights Issue 2015
Valneva announces the launch of a capital increase with shareholders preferential subscription rights of approximately EUR 45 million.
Rights Issue 2013
In December 2012, the Management Boards of Vivalis SA and Intercell AG announced that they have agreed the terms of a merger to create the newly-named Valneva SE, a leading European biotechnology company in vaccines and antibodies.
The shareholders of both Intercell and Vivalis have approved the merger in their respective shareholder meetings on February 27, 2013 and March 7, 2013.
The merger was completed on May 28, 2013.